Participated · Series C · Mar 2026

QL Biopharma focuses on innovative drugs for chronic metabolic disorders, building a differentiated pipeline of ultra-long-acting, oral, and multi-target peptides to improve patient compliance. Its lead asset, ZT002 (a once-monthly injectable GLP-1RA), is in Phase III weight-loss trials in China after Phase II data showed 13.8 % weight reduction at 24 weeks with minimal GI-related dropouts. Additional programs include ZT006, an oral GLP-1 receptor agonist in Phase II for obesity, and ZT003, a GLP-1/FGF21 dual agonist in Phase I trials in Australia. The company also licenses its semaglutide biosimilar ZT001 to Tonghua Dongbao and Aimeike for diabetes and weight-management indications. Four in-house technology platforms (QLLong, QLOral, QLFold, and QLFusion) span R&D through commercial-scale production, backed by a recently approved manufacturing facility. Proceeds will accelerate clinical advancement, regulatory filings, and commercialization of its metabolic disease portfolio. No revenue or user metrics were disclosed in the articles.

Participated · Series D · Feb 2026

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on improving musculoskeletal health through innovative biologic treatments. Its pipeline currently features three clinical candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The company recently completed enrollment in its Phase 2 ARTEMIS trial of AGA2118 and has initiated dosing in the Phase 2 IDUN trial evaluating AGA2115. Proceeds from its latest financing will also advance these programs and other undisclosed pipeline assets. Headquartered in Westlake Village, California, Angitia leverages extensive bone biology expertise and rational drug design to address clear unmet medical needs in serious musculoskeletal diseases. No commercial products have been approved yet, reflecting the firm’s clinical-stage status.

Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.

Participated · Series B · Sep 2025

Avenzo Therapeutics is focused on creating potential best-in-class treatments for cancers with high unmet need. Its pipeline now includes four clinical-stage assets: AVZO-021, a selective CDK2 inhibitor in Phase 1 trials for advanced solid tumors and HR+/HER2- metastatic breast cancer; AVZO-023, a selective CDK4 inhibitor in Phase 1/2 trials for similar indications; AVZO-1418, an EGFR/HER3 bispecific antibody-drug conjugate in Phase 1/2; and AVZO-103, a Nectin4/TROP2 bispecific ADC slated to enter Phase 1/2 studies in 2025. The company has rapidly expanded its clinical portfolio from one to four programs within the past year. Avenzo has raised a total of $446 million to date, including a $386 million Series A/A-1 in November 2024 and the recently closed Series B round. These funds are earmarked to advance clinical development and broaden the company’s oncology pipeline. Headquartered in San Diego, Avenzo is led by co-founder, president, and CEO Athena Countouriotis, M.D.

Participated · Equity · Aug 2025

Minghui Pharmaceutical is a late-stage clinical biopharmaceutical company led by CEO Dr. Guoqing Cao, focused on developing new medicines for oncology and immunology. The company leverages proprietary technology platforms to build a differentiated pipeline of novel therapies. Its clinical priorities include a PD-1/VEGF bispecific antibody and combination strategies with antibody-drug conjugates (ADCs). Minghui also plans a commercial launch of a topical JAK inhibitor in China. The company intends to use new financing to advance its clinical programs and support the planned product launch. Headquarters are in Singapore.